Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRESENTED DATA UNDERSCORE THE POTENTIAL OF LASME-CEL (UCART22) AND ETI-CEL (UCART20X22) TO IMPROVE OUTCOMES IN R/R B-ALL AND R/R NHL: LASME-CEL IN R/R B-ALL (BALLI-01) ORR OF 68% WITH LASME-CEL PROCESS 2 (N=22), 83% AT RP2D (N=12) AND 100% IN THE TARGET PHASE 2 POPULATION (N=9) MEDIAN OS OF 14.8 MONTHS IN PATIENTS WHO ACHIEVED MRD-NEGATIVE CR/CRI FIRST INTERIM ANALYSIS FOR THE BALLI-01 TRIAL EXPECTED IN Q4 2026 ETI-CEL IN R/R NHL (NATHALI-01) ORR OF 86% AND 57% CR RATE (N=7) DEVELOPMENT UPDATE TO BE PRESENTED AT THE ASH 2025 ANNUAL MEETING FULL PHASE 1 DATASET EXPECTED TO BE SHARED IN 2026 SERVIER ARBITRATION: ARBITRAL DECISION EXPECTED TO BE RENDERED ON OR BEFORE DECEMBER 15, 2025 CASH, CASH EQUIVALENTS AND FIXED-TERM DEPOSITS OF $225 MILLION AS OF SEPTEMBER 30, 2025 1 PROVIDES RUNWAY INTO H2 2027 NEW YORK, NOV. 07, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY PROVIDED FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 ENDING SEPTEMBER 30, 2025 AND BUSINESS UPDATES. WE ARE PROUD OF THE PROMISING DATA FROM OUR CORE CLINICAL PRODUCT CANDIDATES.

CELLECTIS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, NOV. 03, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, ANNOUNCED TODAY THE ACCEPTANCE OF TWO ABSTRACTS FOR POSTER PRESENTATION AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2025 ANNUAL MEETING TAKING PLACE FROM DECEMBER 6 TO 9, 2025, IN ORLANDO, FL.

CELLECTIS TO PRESENT A DEVELOPMENT UPDATE FOR ETI-CEL AT ASH 2025

NEW YORK, OCT. 31, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS- NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 ENDING SEPTEMBER 30, 2025 ON FRIDAY, NOVEMBER 7, 2025 AFTER THE CLOSE OF THE US MARKET.

CELLECTIS TO REPORT THIRD QUARTER FINANCIAL RESULTS ON NOVEMBER 7, 2025

 EFFICACY: ORR OF 68% WITH LASME-CEL PROCESS 2 (N=22), 83% AT RP2D (N=12) AND 100% IN THE TARGET PHASE 2 POPULATION (N=9)

CELLECTIS' R&D DAY HIGHLIGHTS LASME-CEL'S POTENTIAL TO ADDRESS SIGNIFICANT UNMET NEED FOR PATIENTS WITH R/R B-ALL

NEW YORK, OCT. 16, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY HOSTS A R&D DAY IN NEW YORK CITY. THE COMPANY'S LEADERSHIP TEAM AND KEY OPINION LEADERS WILL PRESENT THE FULL PHASE 1 DATASET AND OUTLINE THE PIVOTAL PHASE 2 TRIAL DESIGN AND COMMERCIAL OPPORTUNITY FOR LASME-CEL IN R/R B-ALL.

CELLECTIS HOSTS R&D DAY TODAY SHOWCASING PIPELINE PROGRESS AND LONG-TERM VALUE DRIVERS

NEW YORK, OCT. 07, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, ANNOUNCED TODAY THAT FINDINGS HIGHLIGHTING THE STRONG POTENTIAL OF CIRCULAR SINGLE-STRANDED DNA (CSSDNA) AS A UNIVERSAL, EFFICIENT NON-VIRAL TEMPLATE FOR GENE THERAPY, ALONG WITH A COMPREHENSIVE STUDY OF TALE BASE EDITORS (TALEB) OFF-TARGETS IN THE NUCLEAR GENOME, WILL BE PRESENTED AT THE EUROPEAN SOCIETY OF CELL AND GENE THERAPY (ESGCT) ANNUAL CONGRESS, THAT WILL TAKE PLACE ON OCTOBER 7-10, 2025, IN SEVILLA, SPAIN.

CELLECTIS TO PRESENT DATA ON NON-VIRAL GENE THERAPY AND TALE BASE EDITORS AT THE ESGCT ANNUAL CONGRESS

NEW YORK, AUG. 04, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY PROVIDED FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 ENDING JUNE 30, 2025 AND BUSINESS UPDATES.

CELLECTIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS & BUSINESS UPDATES

NEW YORK, JULY 28, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS- NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 ENDING JUNE 30, 2025 ON MONDAY AUGUST 4, 2025 AFTER THE CLOSE OF THE US MARKET.

CELLECTIS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 4, 2025

NEW YORK, JUNE 26, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (EURONEXT GROWTH: ALCLS; NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, HELD TODAY A SHAREHOLDERS GENERAL MEETING AT 2:30 P.M. CET AT THE BIOPARK AUDITORIUM, 11 RUE WATT, 4TH FLOOR, 75013 PARIS, FRANCE.

CELLECTIS REPORTS RESULTS FROM SHAREHOLDERS MEETING HELD ON JUNE 26, 2025

NEW YORK, MAY 21, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, ANNOUNCED TODAY THAT IT WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 26, 2025 AT 2:30 P.M. CET AT THE BIOPARK AUDITORIUM, 11 RUE WATT, 4TH FLOOR, 75013 PARIS, FRANCE.

CELLECTIS' ANNUAL SHAREHOLDERS GENERAL MEETINGTO BE HELD ON JUNE 26, 2025

NEW YORK, MAY 12, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS - NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY PROVIDED FINANCIAL RESULTS FOR THE FIRST QUARTER 2025, ENDING MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE.

CELLECTIS REPORTS FINANCIAL RESULTSFOR THE FIRST QUARTER 2025

NEW YORK, MAY 06, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE COMPANY) (EURONEXT GROWTH: ALCLS- NASDAQ: CLLS), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER 2025 ENDING MARCH 31, 2025 ON MONDAY, MAY 12, 2025 AFTER THE CLOSE OF THE US MARKET.

Cellectis S.A.

CLLS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cellectis S.A.

CLLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CLLS